Program to improve treatment adherence in cystic fibrosis patients
Improving Therapeutic Adherence of Adult Patients With Cystic Fibrosis: Impact of a Co-constructed Program by Patients and Health Caregivers.
This study is testing a new program designed with input from cystic fibrosis patients and healthcare professionals to help adults with cystic fibrosis stick to their treatment plans better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 450 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 3 sites (Clermont-Ferrand and 2 other locations) |
| Trial ID | NCT03226795 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a co-constructed program that involves both patients and healthcare professionals to enhance therapeutic adherence in adults with cystic fibrosis. The program will be implemented and evaluated across three cystic fibrosis centers in the Auvergne-Rhône-Alpes region of France. The intervention focuses on providing information, motivation, and behavioral skills to support patients in managing their condition effectively. By actively involving patients in the creation of the program, the study seeks to address the unique challenges they face in adhering to treatment regimens.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 or older with cystic fibrosis who reside in the Auvergne-Rhône-Alpes region and can communicate in French.
Not a fit: Patients who have undergone transplantation or those who participated in the working group for the co-construction of the intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve treatment adherence and health outcomes for patients with cystic fibrosis.
How similar studies have performed: While no previous programs have demonstrated effectiveness in improving therapeutic adherence for cystic fibrosis, this co-constructed approach is innovative and may offer new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with Cystic Fibrosis * Aged 18 or more * Speaking / understanding French * Followed in one of the participating centers (CRCM of the Auvergne-Rhône-Alpes region) * Resident in Auvergne-Rhône-Alpes * Affiliated to the general health insurance scheme Exclusion Criteria: * Transplanted Patients * Patients who participated in the working group for the co-construction of the intervention
Where this trial is running
Clermont-Ferrand and 2 other locations
- CRCM mixte, Hôpital Estaing — Clermont-Ferrand, France (Recruiting)
- CRCM Adulte CHU Grenoble Alpes — La Tronche, France (Recruiting)
- Centre de Ressources et de Compétences de la Mucoviscidose adulte de Lyon - Centre Hospitalier Lyon Sud — Pierre-Bénite, France (Recruiting)
Study contacts
- Study coordinator: Quitterie REYNAUD
- Email: Quitterie.reynaud@chu-lyon.fr
- Phone: 4 78 86 13 56
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.